The global pancreatic adenocarcinoma treatment market is estimated to garner a large revenue and grow at a CAGR of ~7% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the rising geriatric population around the world, increasing consumption of alcohol and smoking, and growing prevalence of obesity. According to the World Health Organization, 8.873 percent of the total population of the world was aged 65 years or above in 2018, which grew up to 9.318 percent in 2020. Along with these, escalating shift in the lifestyle of people and changing dietary preferences are also expected to boost the growth of the market in the forthcoming years. Furthermore, researchers and medical professionals all around the world are extensively being involved in developing innovative and more effective treatments for pancreatic cancer, which is a crucial factor projected to offer abundant growth opportunities to the market in the near future. CLICK TO DOWNLOAD SAMPLE REPORT
The market is segmented by type into chemotherapy, targeted therapy, and others, out of which, the targeted therapy segment is anticipated to hold the largest share in the global pancreatic adenocarcinoma treatment market on account of the growing introduction of new targeted therapies and biological therapies to minimize the after effects of existing therapies such as chemotherapy. In addition, on the basis of affected area, the exocrine segment is predicted to acquire the largest share during the forecast period, which can be credited to the fact that most of the types of pancreatic adenocarcinoma develop in exocrine. Apart from this, growing investments to study pancreatic adenocarcinoma treatment is also assessed to boost the growth of this market segment in the future.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global pancreatic adenocarcinoma treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the North America is estimated to gather the largest share over the forecast period on the back of well-established healthcare infrastructure, presence of large population suffering from the disease and increasing acceptance of pancreatic treatment procedure in the region. As per the National Cancer Institute, in 2021, 60,430 people in the United States are evaluated to suffer from pancreatic cancer. The total number of cases are predicted to rise by 3.2 percent since the previous year. In addition, strong presence of major market players is also expected to expand the region’s market in the upcoming years. Moreover, the market in Asia Pacific is projected to witness noteworthy growth during the forecast period, which can be ascribed to the rising occurrence of pancreatic adenocarcinoma and growing establishment of critical care centers in the region.
The global pancreatic adenocarcinoma treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the global pancreatic adenocarcinoma treatment market includes the following segments:
FREQUENTLY ASKED QUESTIONS
The major factors driving market growth are increasing geriatric population around the world and rising prevalence of obesity.
The market is anticipated to attain a CAGR of ~7% over the forecast period, i.e., 2022 – 2030.
Lack of skilled medical professionals in lower economic regions is estimated to hamper the market growth.
Asia Pacific will provide more business opportunities to the market in the future owing to the rising occurrence of pancreatic adenocarcinoma and growing establishment of critical care centers in the region.
The major players in the market are Amgen Inc., F. Hoffman-La Roche AG, Novartis AG, Pfizer Inc., Aduro Biotech Inc., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by type, affected area, and by region.
The exocrine segment is anticipated to hold largest market size and is estimated to grow at a robust CAGR over the forecast period and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization